1.Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer

Cheng, SS, Qu, YQ, W     More...

Cheng, SS, Qu, YQ, Wu, J, Yang, GJ, Liu, H, Wang, WH, Huang, Q, Chen, F, Li, GD, Wong, CY, Wong, VKW, Ma, DL, Leung, CH     Less

ACTA PHARMACEUTICA SINICA B[2211-3835], Published 2022, Volume 12, Issue 3, Pages 1390-1405

收錄情况： WOS SCOPUS

WOS核心合集引用: 27  2022影響因子:  14.5  发表年影響因子:  14.5 

2.Aurone derivatives as Vps34 inhibitors that modulate autophagy

Li, GD, Boyle, JW, K     More...

Li, GD, Boyle, JW, Ko, CN, Zeng, W, Wong, VKW, Wan, JB, Chan, PWH, Ma, DL, Leung, CH     Less

ACTA PHARMACEUTICA SINICA B[2211-3835], Published 2019, Volume 9, Issue 3, Pages 537-544

收錄情况： WOS SCOPUS

WOS核心合集引用: 15  2022影響因子:  14.5  发表年影響因子:  7.097 

3.MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

Abdelfatah, S, Berg,     More...

Abdelfatah, S, Berg, A, Huang, Q, Yang, L, Hamdoun, S, Klinger, A, Greten, HJ, Fleischer, E, Berg, T, Wong, VKW, Efferth, T     Less

ACTA PHARMACEUTICA SINICA B[2211-3835], Published 2019, Volume 9, Issue 5, Pages 1021-1034

收錄情况： WOS SCOPUS

WOS核心合集引用: 25  2022影響因子:  14.5  发表年影響因子:  7.097